12 mL of blood to be collected for RNA, DNA, and plasma

Intra Cerebral Hemorrhage

Subarachnoid Hemorrhage

Intraventricular Hemorrhage

Nontraumatic Haemorrhage

University of Maryland Medical Center

Recovery After Cerebral Hemorrhage

Recovery After Cerebral Hemorrhage--Improving Outcomes for Patients With Life-Threatening Neurologic Illness

The Barthel scale is an ordinal scale used to measure performance in activities of daily living. Scores range from 0 to 100. A higher score signifies better outcomes, more independent functionality.

The Montreal Cognitive Assessment was developed as a quick screening tool for neurological function. It assesses the domains of attention and concentration, executive function, memory, language, visuoconstructional skills, conceptual thinking, calculation, and orientation. The MoCA has been tested extensively for use in a variety of disorders affecting cognition such as HIV, Huntington's chorea, Multiple Sclerosis, Parkinson's disease, stroke, vascular dementia, and substance abuse in addition to the wellness of older adults. The MoCA has been tested in ages ranging from as young as 49 in two reports to old-old (85+) with a variety of education levels. The total possible score is 30 points with a score of 26 or more considered normal.

The Modified Rankin Scale (mRS) measures degree of disability/dependence after a stroke. Scores range from 0 to 6. A lower score signifies better outcomes, more independent functionality.

Medical history from hospital discharge to three months will help researchers learn of any adverse events or other medical complications.

EQ-5D is a standardised measure of health status developed by the EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D questionnaire also includes a Visual Analog Scale (VAS), by which respondents can report their perceived health status with a grade ranging from 0 (the worst possible health status) to 100 (the best possible health status).

Gunjan Parikh

Assistant Professor

University of Maryland, Baltimore

Every patient is getting the same therapy of rituximab. If day 1 is tolerated at standard infusion then day 14 and beyond will be given as rapid infusion over 90 minutes

Every patient is getting the same therapy of rituximab. If day 1 is tolerated at standard infusion then day 14 and beyond will be given as rapid infusion over 20 hours
Rapid Infusion Rituximab: Participants will receive their first infusion of rituximab at the standard infusion rate provided in the manufacturer labeling. If they tolerate this infusion with a grade 2 of less infusion-related reaction, the next infusion will be administered as a 90 minute rapid infusion.

Rituximab Infusion

Sex: Female, Male

Region of Enrollment

Patients are given therapy on day 1 and if infusion is tolerated with < grade 2 reaction based on the CTCAE v4 then then will proceed to rapid infusion on day 14 which is given over 90 minutes. The number of infusion reaction is measured for all patients and in all infusions given.

day 1 infusion of standard infusion will be given the same to all patients and then assessed

Number of Reactions for Standard Infusion

day 1 infusion of rapid infusion will be given the same to all patients and then assessed

Number of Reactions for Rapid Infusion

Incidence of Infusion Related Reactions With Rapid Infusion Will be Reported

The amount of time spent administering the rituximab will be compared to the time from the first infusion to the second infusion. The change was calculated from two time points as the value at the later time point minus the value at the earlier time point.

The time of infusion will be recorded from the first dose and the second dose
Time in day hospital: time between the two doses will recorded

Time in Day Hospital

Change in Chair Time With Rapid Infusion Will be Reported

Patients are given therapy on day 1 and if infusion is tolerated with < grade 2 reaction based on the CTCAE v4 then then will proceed to rapid infusion on day 14 which is given over 90 minutes. The grade of infusion reaction is measured for all patients and in all infusions given. According to the National Cancer Institute, there are 5 grades of IRR. In general, grade 1 reactions are classified as asymptomatic or only mild symptoms that do not require intervention. Grade 2 reactions are classified as moderate with minimal, local, or noninvasive interventions required. Grade 3 reactions are classified as severe and medically significant, but not immediately life-threatening. These reactions require hospitalization or prolongation of a current hospitalization. Grade 4 reactions are classified as life-threatening with urgent interventions required. Grade 5 reactions are classified as death related to an adverse drug event.

day 1 infusion of standard infusion will be graded according to CTCAE

Grade of Reactions for Standard Infusion

day 14 infusion of standard infusion will be graded according to CTCAE

Grade of Reactions for Rapid Infusion

Grade of Infusion Related Reactions With Rapid Infusion Will be Reported

Every patient is getting the same therapy of rituximab. If day 1 is tolerated at standard infusion then day 14 and beyond will be given as rapid infusion over 90 minutes
Rapid Infusion Rituximab: Participants will receive their first infusion of rituximab at the standard infusion rate provided in the manufacturer labeling. If they tolerate this infusion with a grade 2 of less infusion-related reaction, the next infusion will be administered as a 90 minute rapid infusion.

Overall Study

LeAnne Kennedy

Multiple Sclerosis

Participants will receive their first infusion of rituximab at the standard infusion rate provided in the manufacturer labeling. If they tolerate this infusion with a grade 2 of less infusion-related reaction, the next infusion will be administered as a 90 minute rapid infusion.

Wake Forest Baptist Medical Center

Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases

Wake Forest University Health Sciences

Semiselective immunoadsorption (GAM peptide adsorber)

Semiselective immunoadsorption (GAM peptide adsorber) in combination with membrane filtration

myasthenia gravis/حمى

Recovery After Cerebral Hemorrhage

Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases

ABO Blood Group Antibody Elimination by a Combination of Semiselective Immunoadsorption Therapy and Membrane Filtration

قاعدة بيانات الأعشاب الطبية الأكثر اكتمالا التي يدعمها العلم